How should a skin reaction (rash, urticaria, or pruritus) to pegfilgrastim (pegylated granulocyte colony‑stimulating factor) be managed?

Management of Skin Reactions to Pegfilgrastim

For mild skin reactions (rash, urticaria, pruritus) to pegfilgrastim, continue the drug and treat symptomatically with topical corticosteroids and oral antihistamines; however, permanently discontinue pegfilgrastim if serious allergic reactions or anaphylaxis occur 1.

Severity-Based Management Algorithm

Grade 1 (Mild/Localized Reactions)

• Continue pegfilgrastim at current dose
• Apply topical moderate-to-high potency corticosteroids (mometasone furoate 0.1% ointment or betamethasone) 2
• Consider oral antihistamines for pruritus
• Monitor for progression over 2 weeks 2

Grade 2 (Moderate/Widespread Reactions)

• Continue pegfilgrastim while treating symptoms
• Escalate to:
  • Topical high-potency steroids AND
  • Oral antihistamines OR
  • GABA agonists (pregabalin/gabapentin) for severe pruritus 2
• Reassess after 2 weeks; if worsening, proceed to Grade 3 management 2

Grade 3 or Serious Allergic Reactions

• Permanently discontinue pegfilgrastim 1
• This is a contraindication to future use 1
• Aggressive symptomatic treatment with corticosteroids and antihistamines
• Do NOT attempt rechallenge—serious allergic reactions can recur even after initial anti-allergic treatment 1

Critical Distinctions

Timing matters for diagnosis: The FDA label emphasizes that serious allergic reactions, including anaphylaxis, typically occur upon initial exposure but can recur within days after discontinuation of anti-allergic treatment 1. Case reports document both immediate anaphylaxis 3 and delayed hypersensitivity reactions occurring more than a week after administration 4.

PEGylation is the culprit: The polyethylene glycol (PEG) component can trigger both IgE-mediated and non-IgE-mediated immune responses 3. Patients who develop reactions to pegfilgrastim may tolerate non-pegylated filgrastim 3, 5.

Common Pitfalls to Avoid

1. Do not rechallenge after Grade 3+ reactions: Unlike some chemotherapy agents where desensitization protocols exist, the FDA label explicitly contraindicates pegfilgrastim in patients with serious allergic reactions 1

2. Distinguish from other causes: Ensure the rash is not from concurrent chemotherapy agents, as management differs significantly. Document timing relative to pegfilgrastim administration 4, 6

3. Monitor for progression: Even mild reactions can evolve into serious hypersensitivity. The 2-week reassessment window is critical 2

4. Consider alternative G-CSF products: If pegfilgrastim must be discontinued, non-pegylated filgrastim or lenograstim are alternatives, though cross-reactivity can occur 5

Practical Management Points

For prevention in all patients receiving pegfilgrastim, provide gentle skin care instructions 2. For mild pruritus, menthol 0.5% topical preparations can provide symptomatic relief 2. The evidence base for pegfilgrastim-specific dermatologic reactions is limited to case reports 3, 4, 6, so the management framework draws from broader ESMO guidelines for anticancer agent-related skin toxicity 2 and infusion reactions 7, combined with explicit FDA contraindications 1.